
Problem statement
Preparing Health Technology Assessment (HTA) submissions for market access requires pulling together clinical, economic, and comparator evidence from many sources, a process that's slow and hard to standardize across markets. Build an HTA market access tool that organizes and structures the evidence needed for HTA dossiers, helping market access teams prepare stronger submissions faster.
One-pager
HTA Insight Navigator
Market Access Intelligence Prototype
AI-powered multi-country HTA evidence intelligence for market access planning
01 PROTOTYPE OVERVIEW Prototype Overview |
Prototype Name: HTA Insight Navigator |
HTA Insight Navigator is an AI-powered prototype that enables pharmaceutical market access teams to rapidly assess publicly available clinical evidence and Health Technology Assessment (HTA) considerations across multiple countries. By consolidating evidence sources, HTA frameworks, and market access insights into a single interface, the solution helps teams accelerate evidence discovery, compare country-specific requirements, and support early market access strategy development.
02 WHAT THE PROTOTYPE IS ABOUT What the Prototype Is About |
Preparing market access strategies requires teams to review clinical evidence, understand country-specific HTA methodologies, and navigate multiple public information sources such as PubMed, ClinicalTrials.gov, NICE, and G-BA. This process is often manual, fragmented, and time-consuming.
HTA Insight Navigator provides a unified evidence intelligence workspace where users can select a drug, indication, and line of therapy to generate structured HTA insights, compare market access considerations across countries, and quickly access relevant evidence sources.
03 KEY FEATURES Key Features |
Multi-Country HTA Comparison – Compare HTA frameworks, evidence expectations, reimbursement considerations, and market access risks across Germany, the UK, and the US. | Evidence Intelligence – Generate direct evidence search links to PubMed and ClinicalTrials.gov for the selected drug and indication. |
Therapy-Specific Context – Display indication-specific HTA considerations, including oncology, rare diseases, and other therapeutic areas. | Market Access Insights – Summarize key evidence expectations, comparator considerations, pricing implications, and potential market access risks. |
Evidence Navigation – Provide quick access to publicly available scientific literature and clinical trial registries from a single interface. |
04 EXPECTED BUSINESS IMPACT Expected Business Impact |
HTA Insight Navigator helps market access and HEOR teams reduce manual evidence discovery efforts while improving consistency in early access planning. The prototype is expected to:
Accelerate evidence discovery and literature review | Improve visibility into country-specific HTA requirements | Support consistent cross-country market access assessments | Enable faster identification of evidence gaps |
Strengthen collaboration across Market Access, Medical Affairs, and HEOR teams |
05 INTENDED AUDIENCE Intended Audience |
Global Market Access Teams | HEOR & Evidence Generation Teams | Pricing & Reimbursement Specialists |
Medical Affairs | Commercial Strategy & Launch Excellence Teams | Market Access Consultants |
06 FDX CONTEXT FDX Context |
HTA Insight Navigator demonstrates Agilisium's FDX approach by combining AI with market access domain expertise to streamline evidence intelligence workflows. The prototype showcases how AI-assisted evidence discovery can support informed, transparent, and efficient market access planning while leveraging publicly available scientific and HTA resources. |